In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therapy for adolescents and adults with spinal muscular ...
Psychedelics have demonstrated significant progress, with promising data and increased interest from large companies, ...
PE: How will FDA's Priority Review Program impact domestic manufacturing? Conrad: A company is not going to de novo set up a new US-based manufacturing site just for this voucher. They cost billions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback